Litigation Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals U.S.A., Inc. (D. Del. 2023)

Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals U.S.A., Inc. (D. Del. 2023)

Docket		Date Filed	2023-02-10
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Jennifer L. Hall
Jury Demand	None	Referred To
Patents	10,071,977; 10,149,829; 8,785,492; RE46,604
Link to Docket	External link to docket

Details for Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals U.S.A., Inc. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2023-02-10	53	Opinion	, 2018) (adding U.S. Patent No. 10,071,977); see Def. Br. at 5 (noting 15 patents asserted in total). …5. Vanda holds multiple patents relating to tasimelteon. The suit for patent infringement underlying …motion to transfer concerns U.S. Patent No. 11,285,129 (the ’129 patent), which issued on March 29, 2022…related patents. 2 See Compl. ¶¶ 22-39, Vanda Pharms. 2 Vanda originally asserted six patents but added…later-issued patents to the Delaware litigation, Vanda would not assert any additional patents against Teva	External link to document
2023-04-14	86	Brief - Opening Brief in Support	the patents asserted by Vanda were U.S. Patent Nos. RE46,604 (“the RE604 patent”) and 10,149,829 (“the…pleadings that claims 1-3 of U.S. Patent No. 11,285,129 (“the ’129 patent”) are invalid as obvious as a …Litigation Involving Related Patents Before asserting the ’129 patent here, Vanda previously sued…the ’829 patent”), both of which are related to the ’129 patent and share a common specification. Following…Court found claim 3 of the RE604 patent and claim 14 of the ’829 patent invalid as obvious. See Vanda Pharm	External link to document
2023-05-12	94	Complaint - Amended	of U.S. Patent No. RE46,604 (“the RE604 patent”) and claim 14 of U.S. Patent No. 10,149,829 (“the ’829…’129 patent was not asserted in the prior litigation, the patentable weight and/or patentability of the…’129 patent was not asserted in the prior litigation, the patentable weight and/or patentability of other…Complaint for infringement of U.S. Patent No. 11,285,129 (the ’129 patent) against Defendant Teva Pharmaceuticals… THE PATENT-IN-SUIT The ’129 Patent 11.	External link to document
2023-06-28	99	Brief - Opening Brief in Support	the patents asserted by Vanda were U.S. Patent Nos. RE46,604 (“the RE604 patent”) and 10,149,829 (“the…pleadings that claims 1-3 of U.S. Patent No. 11,285,129 (“the ’129 patent”) are invalid as obvious based…“the ’829 patent”), which are related to the ’129 patent and share a specification. Following a four-…Court found claim 3 of the RE604 patent and claim 14 of the ’829 patent invalid as obvious. Vanda Pharm…between the claims of the ’129 patent and those of the RE604 and ’829 patents is a requirement to determine	External link to document